Oncology

Shifting provisions of infused chemotherapy from physician offices to hospital outpatient departments (HOPDs) is increasing; however spending for commerical insurers was lower for patients treated in physician offices compared with HOPDs, according to a research letter in JAMA Oncology.

Coverage of updates in value from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of value updates from Patient-Centered Oncology Care, November 16-17, 2018.

Coverage of value updates from Patient-Centered Oncology Care, November 16-17, 2018.

Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of patient-centered care from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.

Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.

A special issue of Evidence-Based Oncology™ provides full coverage of the conference, which The American Journal of Managed Care® presented November 16-17, 2017, in Philadelphia.

The National Comprehensive Cancer Center (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology to help ensure that people living with HIV who are diagnosed with cancer receive safe and necessary treatment.

Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of digital technology updates at Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of digital technology updates from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of digital technology updates from Patient-Centered Oncology Care, November 16-17, 2017.

Coverage of the Keynote Address from Patient-Centered Oncology Care, November 16-17, 2017.

Traditionally, objective response rate (ORR) is used as the primary end point for phase 2 trials assessing the efficacy of anticancer therapies. However, in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers, progression-free survival (PFS) is recommended as a primary end point over ORR, according to a study published in JAMA Oncology.

Blood or marrow transplantation (BMT) can have an impact on a patient’s cognitive functioning, affecting a survivor’s ability to integrate with a group of people and return to work. In addition, BMT recipients can experience a weakened memory, a loss of attention and concentration, and difficulty learning.

Kazia Therapeutics Limited, an oncology-focused biotechnology company, announced on Friday that it has received the FDA’s Orphan Drug Designation for its investigational drug, GDC-0084, for the treatment of glioblastoma multiforme, the most aggressive form of primary brain cancer.

Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.

A study to be published in the Journal of the American College of Surgeons found that a safety-net hospital in Florida could perform an esophagectomy, a highly complex operation, with fewer complications and shorter hospital stays than the national average.